Mineralys Therapeutics, Inc. 603170101 05/21/2026 1a. Election of Class III Director for a three-year term to expire at the 2029 annualmeeting of stockholders: Srinivas Akkaraju, M.D., Ph.D. 1b. Election of Class III Director for a three-year term to expire at the 2029 annualmeeting of stockholders: Brian Taylor Slingsby, M.D., Ph.D., M.P.H. 1c. Election of Class III Director for a three-year term to expire at the 2029 annualmeeting of stockholders: Daphne Karydas 2. Ratify the appointment of Ernst & Young LLP as Mineralys Therapeutics, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026. DIRECTOR ELECTIONS AUDIT-RELATED 7903838 0 FOR 7903838 FOR Phathom Pharmaceuticals, Inc. 71722W107 05/19/2026 1a. Election of class I Director to hold office until the 2029 Annual Meeting of Stockholders: Steven Basta 1b. Election of class I Director to hold office until the 2029 Annual Meeting of Stockholders: Theodore R. Schroeder 1c. Election of class I Director to hold office until the 2029 Annual Meeting of Stockholders: Mark Stenhouse 2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. 3. To approve the compensation of the named executive officers on a non-binding advisory basis (""say-on-pay""). DIRECTOR ELECTIONS AUDIT-RELATED COMPENSATION 1493854 0 FOR 1493854 FOR